Octreotide Scan

About Octreotide scans ..

Radiolabeled tracers provide a functional imaging technique to identify neuroendocrine tumours. Currently there are several single-photon techniques available using either 123I-MIBG, 111In-DTPA-pentetreotide (Octreoscan) or 99mTc-EDDA/HYNIC-try3-octreotate.

99mTc-Tektrotyd 9HYNIC-[D-Phel, Tyr3-Octreotide]) is intended for identifying pathological lesions in which over expression of somatostatin receptors occurs (especially subtype 2 and, to a lesser extent, subtypes 3 and 5). 99mTc-Tektrotyd attaches to somatostatin receptors in tissues where, as a consequence of the disease, the cell surfaces contain these receptors in more than the physiological density.

While this is an expensive procedure and has only a limited role in the assessment of these tumours, it can be useful in treatment planning.



  • Gastro-entero-pancreatic neuroendocrine tumours (GEP-NET)

  • Pituitary adenomas

  • Tumours origination in a sympathetic system; pheochromocytoma, paraganglioma, neuroblastoma, ganglioneinoma etc.

  • Medullary carcinoma of thyroid


  • Short acting somatostatin analogues should be stopped 3 days prior to the scan.

  • Lanreotide (long acting analogue) should be stopped at least 3 weeks prior to the scan.

  • Octreotide (long acting analogue) should be stopped at least 5 weeks prior to the scan.

  • A light diet the day before the examination, patient should fast on the day of examination until the end of the study.

  • Patients should increase fluids and empty their bladders frequently.

  • If the patient does not have diarrhoea a laxative should be taken the day before the scan.


  • Scanning is performed at 2 and 4 hours post injection; this includes whole body imaging and SPECT/CT.


rounded corners top

Related Documents

rounded corners bottom
Page last reviewed: 23 March 2015